Deal Tracker · Countries

Brazil pharma deals

10 pharma deals involving Brazil — companies based there or deals covering the market — tracked by EPT: distribution, licensing & localization. Most active: Samsung Bioepis, A.C.Camargo Cancer Center, Bahiafarma & Biocon. Latest: Celltrion → Brazilian federal government (Supply / Manufacturing, 17 Nov 2026).

10
deals tracked
9
announced in 2026
$50.5m
disclosed value (1 deal)
30%
distribution, the top deal type
  • EPT has tracked 10 Brazil pharma deals (2022–2026), 9 of them announced in 2026.
  • The most common structures are distribution (30%), licensing (30%) & localization (20%).
  • Values were disclosed for 1 of 10 deals, totalling $50.5m; the largest is Shanghai Henlius Biotech → Eurofarma ($50.5m, 11 May 2022).
  • The most active companies: Samsung Bioepis (2).

Most active companies

Samsung Bioepis (2)

Countries involved

Argentina (4) · Mexico (3) · South Korea (3) · Switzerland (3) · Colombia (2) · Canada (1)

Largest disclosed deals

Questions

How many Brazil pharma deals has EPT tracked?
10 as of 17 Nov 2026, covering 2022–2026; 9 were announced in 2026. The most recent is Celltrion → Brazilian federal government (Supply / Manufacturing, 17 Nov 2026).
What types of Brazil pharma deals are most common?
Distribution: 3 (30%); Licensing: 3 (30%); Technology transfer / Localization: 2 (20%); Partnership / Collaboration: 1 (10%).
Which companies are most active in Brazil pharma deals?
Samsung Bioepis (2 deals).
What is the largest disclosed Brazil pharma deal?
Shanghai Henlius Biotech → Eurofarma: $50.5m (Licensing, 11 May 2022). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · India (19) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)